Intra-Cellular Therapies Announces Special Shareholder Meeting Amid Johnson & Johnson Merger Lawsuits
Bedminster, NJ – March 18, 2025 – Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) has announced that a special shareholder meeting will be held on March 27, 2025, regarding its merger with Johnson & Johnson (NYSE: JNJ).

Key Developments:
Merger Details:
Johnson & Johnson plans to acquire Intra-Cellular Therapies, with the company becoming a wholly owned subsidiary.
Shareholders as of February 13, 2025, can vote on the proposed merger.
Legal Challenges:
Multiple lawsuits have been filed by shareholders, alleging incomplete or misleading disclosures in the company's proxy statement regarding the merger.
Plaintiffs seek injunctive relief, corrective disclosures, and potential monetary damages.
Company Response:
Intra-Cellular Therapies denies all allegations and has voluntarily supplemented its proxy statement to avoid litigation costs and delays.
Despite these challenges, the merger remains on track, with Intra-Cellular Therapies urging shareholders to review all relevant materials and vote accordingly before the upcoming meeting.